Case Study — Diagnostics / Federal Commercialization

Accelerating diagnostic technologies from technical promise to national deployment

A national diagnostics emergency required commercialization, regulatory, manufacturing, and deployment work to run in parallel. The advisory role sat where technical promise had to become adopted capability.

Client Type
National Institutes of Health / RADx Tech
Sector
Diagnostics / Federal Commercialization
Engagement
Commercialization Infrastructure / Federal Capital Strategy & Program Positioning
Horizon
2020–2023

1,042

Proposals evaluated (NIH-reported)

55

FDA EUA tests (NIH-reported)

7.8B+

Tests and test products produced (NIH-reported)

Problem

  • Validation, regulatory clearance, manufacturing scale-up, and market adoption could not run sequentially.
  • Diagnostic teams were technically strong but had no route to procurement, adoption, and federal buyers.
  • A conventional grant program could not make milestone-driven acceleration decisions at the required tempo.

Intervention

  1. 01

    Commercialization Read

    Assessed venture commercialization posture, market strategy, and the gaps between technical milestones and adoption.

  2. 02

    Adoption Pathways

    Mapped procurement, government opportunity, strategic partners, and federal/defense-adjacent buyers against each technology.

  3. 03

    Milestone Sprints

    Supported milestone-driven commercialization sprints and vendor/partner assessment inside the program's operating cadence.

  4. 04

    Program Decisions

    Contributed expert input to program operating decisions on readiness, partners, and deployment routes.

Result

  • 1,042 proposals evaluated across the initiative
  • More than 250 organizations funded
  • 55 FDA Emergency Use Authorization tests
  • More than 7.8 billion tests and test products produced as of April 2023

Attribution & Disclosure

  • National Institutes of Health
  • NIBIB / RADx Tech
  • VentureWell

Heath Naquin served as an NIH RADx Core Expert / commercialization advisor through VentureWell. Program-level outcomes are reported by NIH and are not solely attributable to any individual advisor or to Forged Catalyst.

Public national-program case — Heath's role is described separately from NIH-reported program outcomes. Institutional references describe program context and do not imply endorsement.

Engage

Is this the same constraint you're carrying?

The Capital Strategy Diagnostic takes about three minutes and returns a structured read on where conversion is breaking down.